Taft Pharmaceutical and Life Science Litigation attorneys Roshan Shrestha, Ph.D. and Andrew Alul wrote “Fed. Circ. Ruling Reaffirms Listing Elements Separately Is Key” for Law360 on April 1 on the U.S. Court of Appeals for the Federal Circuit’s March 14 opinion in Regeneron Pharmaceuticals Inc. v. Mylan Pharmaceuticals Inc. The decision reaffirmed that when a patent claim lists elements separately, they are considered distinct elements.

Read the full article here.

Shrestha focuses his practice on all aspects of intellectual property law, including patent litigation, prosecution, and opinion work in the chemical, pharmaceutical, and electronic material arts. He has a broad scope of pharmaceutical and life sciences capabilities, including Hatch-Waxman litigation and inner parts review proceedings at the USPTO. Shrestha has been recognized by Super Lawyers and Leading Lawyers Network and was named to Law Bulletin’s “40 Illinois Attorneys Under 40 to Watch.”

Alul focuses his practice on intellectual property litigation and counseling, particularly pharmaceutical drug patent litigation and regulatory litigation involving the FDA. He has extensive experience litigating cases brought under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act for pharmaceutical products and under the Administrative Procedures Act.